Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)
March 16, 2023 06:56 AM EDT
Deals

Roy­al­ty Phar­ma nabs $475M mile­stone from Pfiz­er up­on mi­graine nasal spray OK

Amber Tong

The FDA’s re­cent ap­proval of Pfiz­er’s mi­graine nasal spray was al­so good news for Roy­al­ty Phar­ma, trig­ger­ing a whop­ping $475 mil­lion mile­stone pay­ment. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times